Literature DB >> 12565184

Description and predictors of direct and indirect costs of pain reported by cancer patients.

Barry V Fortner1, Gail Demarco, Gordon Irving, Jeri Ashley, Ginny Keppler, Jana Chavez, Jana Munk.   

Abstract

The purpose of this study was to describe direct and indirect costs associated with pain in cancer patients and to examine potential predictors of these costs. The study surveyed cancer outpatients about direct costs resulting from pain-related hospitalizations, emergency department visits, physician office visits, and use of analgesic medications and indirect costs related to money spent on pain-related transportation, complementary methods to improve pain management, educational materials, over-the counter medication, domestic support, and childcare. Furthermore, the study examined age, marital status, race, income level, pain severity, pain interference, and presence of breakthrough pain as predictors of direct and indirect costs. Three hundred and seventy-three cancer outpatients were sampled. One hundred and forty-four cancer patients (39%) reported experiencing cancer-related pain and completed the study questionnaires. Seventy-six percent (76%) of the patients had experienced at least one pain-related cost, resulting in an average monthly direct cost of US$ 891/month per patient. Sixty-nine percent (69%) of patients had experienced some type of direct medical cost due to pain, resulting in an average total direct pain-related cost of US$ 825/month per patient. Fifty-seven percent (57%) of patients reported incurring at least one indirect pain-related expense for an average indirect cost of US$ 61/month per patient. Higher pain intensity, greater pain interference, and presence of breakthrough pain predicted higher direct and indirect medical expenses. Younger age and lower income level also predicted higher direct medical expenses.

Entities:  

Mesh:

Year:  2003        PMID: 12565184     DOI: 10.1016/s0885-3924(02)00597-3

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  29 in total

Review 1.  Substance abuse in cancer pain.

Authors:  Tatiana D Starr; Lauren J Rogak; Steven D Passik
Journal:  Curr Pain Headache Rep       Date:  2010-08

Review 2.  Developing effective cancer pain education programs.

Authors:  Michelle Y Martin; Maria Pisu; Elizabeth A Kvale; Shelley A Johns
Journal:  Curr Pain Headache Rep       Date:  2012-08

3.  Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON).

Authors:  J Porta-Sales; C Pérez; Y Escobar; V Martínez
Journal:  Clin Transl Oncol       Date:  2015-12-22       Impact factor: 3.405

Review 4.  [Cancer breakthrough pain. Indications for rapidly effective opioids].

Authors:  J Kessler; H J Bardenheuer
Journal:  Anaesthesist       Date:  2011-07       Impact factor: 1.041

5.  [Experiences of cancer patients with breakthrough pain and pharmacological treatments].

Authors:  L Bertram; S Stiel; F Elsner; L Radbruch; A Davies; F Nauck; B Alt-Epping
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

6.  Cancer pain--progress and ongoing issues in New Zealand.

Authors:  W J Landman; B A Foggo
Journal:  Pain Res Manag       Date:  2009 Sep-Oct       Impact factor: 3.037

Review 7.  Access to opioid analgesics and pain relief for patients with cancer.

Authors:  Shalini Dalal; Eduardo Bruera
Journal:  Nat Rev Clin Oncol       Date:  2013-01-15       Impact factor: 66.675

Review 8.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Reimagine: a randomized controlled trial of an online, symptom self-management curriculum among breast cancer survivors.

Authors:  S K Smith; K MacDermott; S Amarasekara; W Pan; D Mayer; M Hockenberry
Journal:  Support Care Cancer       Date:  2018-08-27       Impact factor: 3.603

10.  Quality of life in cancer patients with pain in beijing.

Authors:  Ping Yang; Li-Qiu Sun; Dong Pang; Yue Ding
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.